

# Laser for Vascular Lesions

**Iris K. Rubin, M.D.**

Medical Director

Dermatologic and Vascular Laser Surgery Program  
Children's National Medical Center

Assistant Clinical Professor of Dermatology  
George Washington University



|                       | <b>Infantile hemangioma</b>  | <b>Port-wine stain</b>  |
|-----------------------|--|---|
| <b>Onset</b>          | <ul style="list-style-type: none"> <li>• First few weeks</li> <li>• Precursor may be present at birth</li> </ul>                   | <ul style="list-style-type: none"> <li>• Present at birth</li> </ul>  |
| <b>Course</b>         | <ul style="list-style-type: none"> <li>• Proliferative period in first year of life, followed by <b>slow involution</b></li> </ul> | <ul style="list-style-type: none"> <li>• <b>Does not regress</b></li> <li>• May become hypertrophic, violaceous with age</li> </ul> |
| <b>Tissue</b>         | <ul style="list-style-type: none"> <li>• GLUT1 positive</li> </ul>   | <ul style="list-style-type: none"> <li>• GLUT1 negative</li> </ul>  |
| <b>Classification</b> | <ul style="list-style-type: none"> <li>• <b>Vascular tumor</b></li> </ul>  | <ul style="list-style-type: none"> <li>• <b>Vascular malformation</b></li> </ul>  |



# Port-Wine Stain: Laser Treatment

- Pulsed dye laser is gold standard
- ~80% improve; < 20% clear completely with laser treatment
- ***Early treatment may offer improved treatment response and clearance***
  - Chapas et al. 89% average clearance, starting treatment before or at 6 months of age



Photo: Bologna et al., *Dermatology*, 2<sup>nd</sup> Edition

Chapas AM, Eickhorst K, Geronemus RG. *Lasers Surg Med* 2007;39:563-368.



# Port-Wine Stain Treated in Infancy

# Port-Wine Stain: Other Treatments

- Deeper penetrating lasers
  - Alexandrite laser (755nm)
  - Nd:Yag laser (1064nm)
- Anti-angiogenesis medications
  - Rapamycin, investigational, not yet studied in children

# Port-Wine Stain Hypertrophy


- Geronemus et al. report  
~65% hypertrophied and/or  
nodular by 5<sup>th</sup> decade
- Mean age hypertrophy 37
- More challenging to treat
- *Why do some hypertrophy  
and others do not?*

# Hemangioma: Role of Laser

- Proliferating lesions?
- Ulcerated hemangioma
- Involuting hemangioma
- Residual hemangioma

# Retrospective Case Review of Pulsed Dye Laser With Cooling

- 90 patients, 105 hemangiomas
- Median age 3 months
- **81% near complete or complete clearance color, 64% for thickness**
- Adverse effects:
  - One minor ulceration
  - 4% hyperpigment
  - 14% hypopigment





# Propranolol & Pulsed Dye Laser: Retrospective Review


- 12 concurrent propranolol + PDL, 5 sequential propranolol then PDL, controls propranolol only
- **More rapid and complete clearance with PDL and propranolol;** lower cumulative propranolol dose for near complete clearance
- Total dose and days on propranolol similar between groups

# Timolol and PDL

- **Timolol and PDL** may be better than timolol or PDL alone
  - Park et al. case review 102 patients with 111 superficial IH. Mean improvement 47% timolol only, 66.5% timolol and PDL

# Laser for Ulcerated Hemangioma

- David et al. 78 patients, **91% response to laser alone**, mean 2 treatments (585nm)
- Kim HJ et al. 22 children, 50% improved, 18% no response, 5% experienced worsening



David LR, Malek MM, Argenta LC. *Br J Plast Surg* 2003;56:317-27.

Kim HJ, Colombo M, Frieden IJ. *J Am Acad Dermatol* 2001;44:962-72.

Rubin I. In: Avram MM, Friedman PM, eds. *Laser & light source treatments for the skin*, 2014.

# Residual Lesion: When to Intervene?

- 15-40% left with residual lesion
- **Most IH do not continue to involute significantly after age 3.5** (Couto RA et al.)




# Ablative Fractional Resurfacing for Involved Hemangioma Residuum (Case Series)



Brightman LA, Brauer JA, Terushkin V et al. *Arch Dermatol* 2012;148:1294-1298.

# Hemangioma Progression



Tollefson MM, Frieden IJ. *Pediatrics* 2012;130:e314-e320

# Can Very Early Treatment Prevent Proliferation?